Skip to main content
. 2021 Apr 26;12:573832. doi: 10.3389/fphar.2021.573832

TABLE 1.

Characteristics of included studies.

Variables Smoking (n = 106) Non-smoking (n = 115) p value
Age
 18–30 7 (6.6) 6 (5.2) 0.3
 31–40 8 (7.5) 19 (16.5)
 41–50 26 (24.5) 27 (23.5)
 51–60 41 (38.7) 34 (29.6)
 >60 24 (22.7) 29 (25.2)
BMI
 <25 2 (1.9) 11 (9.6) 0.04
 25–28 6 (5.7) 4 (3.5)
 >28 98 (92.4) 100 (86.9)
Smoke period
 <10 years 5 (4.7)
 ≥10 years 101 (95.3)
Quit smoking
 Yes 2 (1.9)
 No 104 (98.1)
Muscle relaxants
 Rocuronium 68 (64) 93 (81) 0.008
 Vecuronium 38 (36) 22 (19)
History
 Hypertension 7 (6.6) 13 (11.3) 0.5
 Diabetes 4 (3.8) 2 (1.7)
 Both hypertension and diabetes 2 (1.9) 2 (1.7)
 Others 1 (0.7) 2 (1.7)
 None 92 (87) 96 (83.5)
Surgery type
 Major 8 (7.5) 7 (6.1) 0.9
 Minor 98 (92.5) 108 (93.9)
 PETCO2 35.7 (2.8) 36.4 (3.2) 0.1
 Muscle relaxant onset time (s) 217.1 (55.9) 222.8 (64.4) 0.5
 Muscle relaxant lasting effect time (s) 2420 (738.2) 2582 (847.3) 0.1
 75% recovery 3631 (1003.4) 3711 (1030.3) 0.6
 Recover index 1206 (509.3) 1129 (482.5) 0.2
Usage of antibiotics
 Yes 80 (75.5) 58 (50.4) <0.001
 No 26 (24.5) 57 (49.6)
Type of antibiotics
 cefamandole 2 (1.9) 7 (6.1) 0.0
 cefathiamidine 22 (21.0) 10 (8.7)
 cefoperazone 3 (2.9) 1 (0.9)
 ceftizoxime 6 (5.7) 5 (4.3)
 cefuroxime 28 (26.7) 22 (19.1)
 Levofloxacin 9 (8.6) 6 (5.2)
 Piperacillin 10 (9.5) 7 (6.1)
 None 26 (24.8) 57 (49.6)
Anesthetics
 Propofol 95 (89.6) 91 (79.1) 0.05
 Other 11 (10.4) 24 (20.9)
Opiates
 Sufentanil 103 (97.1) 112 (97.4) 1
 Fentanyl 3 (2.9) 3 (2.6)
Complications
 Yes 4 (3.8) 1 (0.9) 0.3
 No 102 (96.2) 114 (99.1)